Skip to content
DataLookout
Menu

NCT07850063

ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease

StatusNot Yet Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below.

  1. Minor Trial sites expanded: 45 → 55 locations
    • Start date pushed from Nov 18, 2026 to Nov 25, 2026
  2. Minor Trial sites expanded: 34 → 45 locations
    • Start date pushed from Nov 2, 2026 to Nov 18, 2026
  3. Minor Trial sites expanded: 25 → 34 locations
    • Start date pushed from Oct 23, 2026 to Nov 2, 2026
  4. Minor Trial sites expanded: 11 → 25 locations
  5. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Composite average Z-score (dimensionless) at Week 76 of cardiac structural and functional parameters
Timeframe: At week 76

Secondary (8)

Relative change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) from baseline to 76 weeks (%)
Relative change in alanine aminotransferase (ALT) from baseline to 76 weeks (%)
Absolute change in KCCQ from baseline to 76 weeks (dimensionless)
New use of oral loop diuretics during follow-up from baseline to 76 weeks, irrespective of symptoms (yes/no)
Absolute change in systolic blood pressure (SBP) from baseline to 76 weeks (mmHg)
Show 3 moreShow less
Absolute change in fibrosis-4 index (FIB-4) from baseline (dimensionless)
Absolute change in fatty liver index (FLI) from baseline to 76 weeks (dimensionless)
Absolute change in hepatic steatosis index (HSI) from baseline to 76 weeks (dimensionless)

Arms and interventions

Survodutide armExperimental
Placebo armPlacebo comparator

Combination products: Survodutide, Placebo matching survodutide

Sites

55 sites in 6 countries

United States 28, Spain 7, United Kingdom 7, China 6, Germany 6, Japan 1